Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis (CIS-COHORT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01371071
Recruitment Status : Unknown
Verified June 2011 by Charite University, Berlin, Germany. Recruitment status was: Recruiting
A majority of patients with multiple sclerosis initially presents with a single demyelinating event, e.g. in the optic nerves, brain, brainstem or spinal cord, referred to as a clinically isolated syndrome (CIS). Not all patients with CIS get a relapse and develop multiple sclerosis but in those patients who do, irreversible damage of the central nervous system, e.g. axonal damage, is already detectable in that early stage of disease. Early initiation of immunomodulatory therapy is crucial for patients with clinically isolated syndrome who are at high risk for the development of multiple sclerosis. Vice versa identification of low risk patients could help to avoid an unnecessary therapy. In this prospective observational study we want to follow up patients with CIS and early multiple sclerosis over a period of four years and obtain clinical, laboratory and MRI - data in order to identify risk factors for relapses, prognostic factors and therapy response markers.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients will be recruted at neurological outpatient clinics and neurologcial clinics of the charité and neurologists' medical practices.
age > 18 years
signed informed consent
clinically isolated syndrome within the last 6 months
diagnosis of multiple sclerosis within the last two years
eye disease that could interfere with OCT (e.g. glaucoma, diabetic retinopathy)
secondary progressive multiple sclerosis
contraindications for MRI, e.g. pacemaker, metal implants, allergy against gadolinium